Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epinastine intranasal - Inspire Pharmaceuticals

Next Previous
X
Search
Drug Profile

Epinastine intranasal - Inspire Pharmaceuticals

Latest Information Update: 24 Apr 2008

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Inspire Pharmaceuticals
  • Class Antiallergics; Dibenzazepines; Eye disorder therapies; Imidazoles; Nonsedating antihistamines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 24 Apr 2008 Discontinued - Phase-III for Seasonal allergic rhinitis in USA (Intranasal)
  • 18 Mar 2008 Pharmacokinetics data from a phase II trial in seasonal allergic rhinitis presented at the 64th Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI-2008)
  • 29 Nov 2007 Phase-III clinical trials in Seasonal allergic rhinitis in USA (Intranasal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top